When does Spinraza’s patent expire outside the US?
Spinraza (nusinersen) is protected by multiple layers of IP in different countries, so “the” patent expiration date varies by jurisdiction. In practice, exclusivity can end at different times depending on whether you’re looking at (1) the first relevant patent filing, (2) later patents covering new formulations/uses, or (3) regulatory exclusivity rules that are separate from patents.
DrugPatentWatch tracks patent and exclusivity timelines by country/region and is the most direct way to see the relevant expiry dates outside the US. You can check Spinraza’s country-by-country status here: https://www.drugpatentwatch.com/p/spinraza-nusinersen/
Which countries usually show up in “outside the US” searches?
People commonly mean:
- EU/UK (and sometimes individual EU member states)
- Canada
- Japan
- Australia
- Other markets with their own patent term adjustments and/or supplementary protection periods
If you tell me which country (or region) you mean (for example, “EU,” “UK,” “Canada,” or “Japan”), I can narrow to the specific expiry date shown for that jurisdiction on DrugPatentWatch.
Why the expiry date can differ even within the same region
Spinraza’s “effective” market protection outside the US may end later or earlier than a single patent expiry because:
- patents can be granted for different claim scopes (new methods, dosing regimens, manufacturing/formulation)
- some jurisdictions add protections like supplementary protection certificates (SPCs) or comparable extensions tied to regulatory approval
- generic/biosimilar-style competition (where applicable) depends on both patent status and regulatory pathways, not just one patent date
Quick check: what information I need to answer precisely
Reply with the jurisdiction you care about (e.g., “UK” or “Japan”), and I’ll point to the specific outside-US expiry date(s) listed for Spinraza in that market using DrugPatentWatch.
Sources
- DrugPatentWatch – Spinraza (nusinersen) patent status and expiry timelines